HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Clinical trials for HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC explained in plain language.
Never miss a new study
Get alerted when new HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC trials appear
Sign up with your email to follow new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise in early cancer trial
Disease control CompletedThis early-stage study tested a new drug (BGB-A445) alone and with another drug (tislelizumab) in 204 people with advanced solid tumors like lung, head and neck, and nasopharyngeal cancers. The main goal was to check safety and find the best dose. This is not a cure, but aims to …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE1 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
New combo shows promise in head and neck cancer trial
Disease control CompletedThis study tested a new drug (MK-1454) injected directly into tumors, combined with an immunotherapy (pembrolizumab), for adults with advanced head and neck cancer that cannot be removed by surgery. The goal was to see if the combination works better than pembrolizumab alone. The…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 05, 2026 12:07 UTC
-
Shorter radiation may ease burden for older head and neck cancer patients
Symptom relief CompletedThis study tested a shorter radiation treatment schedule for head and neck cancer in people aged 70 and older. Instead of daily visits for 6-7 weeks, the goal was to reduce side effects and help patients complete treatment. The study enrolled 37 participants and looked at whether…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: NA • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Symptom relief
Last updated Jun 15, 2026 19:06 UTC
-
Scientists hunt for clues to predict who benefits from head and neck cancer immunotherapy
Knowledge-focused CompletedThis study looked at 50 people with advanced head and neck cancer that came back or spread. Researchers wanted to find immune system markers in blood and tumor tissue that could predict who would respond to the drug nivolumab. The goal is to better select patients for this treatm…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: NA • Sponsor: Yonsei University • Aim: Knowledge-focused
Last updated Jun 16, 2026 12:53 UTC